Comparative clinical study of ciprofloxacin and cefaclor in the treatment of respiratory tract infections

Hiroyuki Kobayashik; Enji Takamura; Hiroaki Takeda; Kota Kono; Akira Saito; Masumi Tomizawa; Ichiro Nakayama; Yohmei Hiraga; Kohki Kikuchi; Asako Yamamoto; Kazuo Takebe; Yoshihiro Kumasakak; Azumi Aoyagi; Toyokazu Tamura; Keiichi Sekino; Katsumi Endo; Tatsuro Irie; Morio Sagara; Katsuhiro Okamoto; Masao Tamura; Kazuki Konishi; Ataru Daibo; Hiroshi Kuramitsu; Kazutoshi Gomi; Kotaro Itakura; Nobuhisa Sato; Kazuo Tanifuji; Tamotsu Takishima; Shiroh Ida; Isao Ohno; Kiyoshi Konno; Kotaro Oizumi; Seiichi Aonuma; Izumi Hayashi; Masataka Katsu; Shinji Okui; Toshio Fukui; Takashi Yokose; Takeo Toyota; Mieko Kawai; Hajime Yamagata; Shigeo Yoshizawa; Tetsuji Katayama; Teruo Aoyagi; Fuyuhiko Higashi; Gohta Masuda; Masayoshi Negishi; Chenden Young; Minoru Sato; Takehiko Tominaga; Osamu Sekine; Yoshimar Usuda; Nobuki Aoki; Fusanosuke Yamasaku; Yasutoshi Suzuki; Atsushi Saito; Tadashi Miyahara; Masaru Koyama; Kentaro Watanabe; Fukuo Iijima; Keimei Mashimo; Yoshiji Yamane; Masakazu Katoh; Hiroichi Tanimoto; Koichiro Nakata; Yoshitaka Nakamori; Naohiko Chonabayashi; Ryuo Nakatani; Kunihiko Yoshimura; Hideo Ikemoto; Kazuyoshi Watanabe; Junzaburo Kabe; Hiroyoshi Ishibashi; Yasuyuki Sano; Koichiro Kudo; Yuko Uno; Ippei Fujimori; Yoshio Kobayashi; Mitsuo Obana; Takao Okubo; Akira Ito; Makio Kurihara; Kaitaro Yamabe; Kazufuto Fukaya; Fumio Matsumoto; Shigeki Odagiri; Masanori Matsumura; Kaneo Suzuki; Koou Murohashi; Hisako Suzuki; Yasuhiro Yoshiike; Mitsuyo Kiuchi; Tsutomu Fukuda; Shozo Kusama; Yukinori Matsuzawa; Kaoru Ohyama; Toshihiko Takeuchi; Masahito Kato; Hidekazu Hanaki; Toshiyuki Yamamoto; Hideki Nishiyama; Takekuni Iwata; Kazukiyo Oida; Yoshiro Mochizuki; Mitsuo Hase; Yujiro Suzuki; Nobuaki Ikeda; Shozo Fujino; Tetsuya Matsumoto; Hiroyuki Tsujino; Kenji Bando; Naoaki Kuroda; Fumiyuki Kuze; Yuruko Kamoto; Seibun Yonezu; Yube Iida; Yoshihiko Sakakibara; Kōjiro Yasunaga; Yoshihiro Ueda; Hiroshi Ôkubo; Fumio Miki; Yoshiyasu Ikuno; Eiji Inoue; Akihito Murata; Shin Ich Tanizawa; Kazuo Sakamoto; Hirozumi Sakai; Rinzo Soejima; Hiroshi Kawane; Yoshihiti Noki; Yoshihisa Nakagawa; Osamu Moriya; Osamu Kurimura; Hideo Sasaki; Hirofumi Fukuhara; Tadao Morimoto; Eiro Tsubura; Masakazu Tamura; Toshihiro Gotoh; Masaru Nakagawa; Koichi Fukuyama; Tadaaki Morimoto; I. Teiho; Masami Ito; Naoyoshi Kojiro; Yoshiro Sawae; Kaoru Okada; Yukio Kumagai; Hitoshi Nagano; Torao Inoue; Chiharu Kubo; Kohei Hara; Atsushi Saito; Keizo Yamaguchi; Yoji Suzuyama; Yoshiteru Shigeno; Shigeru Kohno; Koichi Watanabe; Kin Ich Izumikawa; Tsunetoshi Koteda; Kazuhiro Okuno; Takashige Miyazaki; Tsuneo Tsutsumi; Keizo Matsumoto; Harumi Shishido; Tomoyuki Harada; Masaru Nasu; Jun Goto; Yoichiro Goto; Takayoshi Tashiro; Takashi Tioga; Shykuro Araki; Masayuki Ando; Moritaka Suga; Kazumine Kobari; Masao Nakatomi; Yutoku Kinjo; Tatsuo Ohgimi; Katsuyoshi Shimoji; Yuei Irabu

doi:10.11250/chemotherapy1953.34.1011

Comparative clinical study of ciprofloxacin and cefaclor in the treatment of respiratory tract infections

Hiroyuki Kobayashik, Enji Takamura, Hiroaki Takeda, Kota Kono, Akira Saito, Masumi Tomizawa, Ichiro Nakayama, Yohmei Hiraga, Kohki Kikuchi, Asako Yamamoto, Kazuo Takebe, Yoshihiro Kumasakak, Azumi Aoyagi, Toyokazu Tamura, Keiichi Sekino, Katsumi Endo, Tatsuro Irie, Morio Sagara, Katsuhiro Okamoto, Masao TamuraKazuki Konishi, Ataru Daibo, Hiroshi Kuramitsu, Kazutoshi Gomi, Kotaro Itakura, Nobuhisa Sato, Kazuo Tanifuji, Tamotsu Takishima, Shiroh Ida, Isao Ohno, Kiyoshi Konno, Kotaro Oizumi, Seiichi Aonuma, Izumi Hayashi, Masataka Katsu, Shinji Okui, Toshio Fukui, Takashi Yokose, Takeo Toyota, Mieko Kawai, Hajime Yamagata, Shigeo Yoshizawa, Tetsuji Katayama, Teruo Aoyagi, Fuyuhiko Higashi, Gohta Masuda, Masayoshi Negishi, Chenden Young, Minoru Sato, Takehiko Tominaga, Osamu Sekine, Yoshimar Usuda, Nobuki Aoki, Fusanosuke Yamasaku, Yasutoshi Suzuki, Atsushi Saito, Tadashi Miyahara, Masaru Koyama, Kentaro Watanabe, Fukuo Iijima, Keimei Mashimo, Yoshiji Yamane, Masakazu Katoh, Hiroichi Tanimoto, Koichiro Nakata, Yoshitaka Nakamori, Naohiko Chonabayashi, Ryuo Nakatani, Kunihiko Yoshimura, Hideo Ikemoto, Kazuyoshi Watanabe, Junzaburo Kabe, Hiroyoshi Ishibashi, Yasuyuki Sano, Koichiro Kudo, Yuko Uno, Ippei Fujimori, Yoshio Kobayashi, Mitsuo Obana, Takao Okubo, Akira Ito, Makio Kurihara, Kaitaro Yamabe, Kazufuto Fukaya, Fumio Matsumoto, Shigeki Odagiri, Masanori Matsumura, Kaneo Suzuki, Koou Murohashi, Hisako Suzuki, Yasuhiro Yoshiike, Mitsuyo Kiuchi, Tsutomu Fukuda, Shozo Kusama, Yukinori Matsuzawa, Kaoru Ohyama, Toshihiko Takeuchi, Masahito Kato, Hidekazu Hanaki, Toshiyuki Yamamoto, Hideki Nishiyama, Takekuni Iwata, Kazukiyo Oida, Yoshiro Mochizuki, Mitsuo Hase, Yujiro Suzuki, Nobuaki Ikeda, Shozo Fujino, Tetsuya Matsumoto, Hiroyuki Tsujino, Kenji Bando, Naoaki Kuroda, Fumiyuki Kuze, Yuruko Kamoto, Seibun Yonezu, Yube Iida, Yoshihiko Sakakibara, Kōjiro Yasunaga, Yoshihiro Ueda, Hiroshi Ôkubo, Fumio Miki, Yoshiyasu Ikuno, Eiji Inoue, Akihito Murata, Shin Ich Tanizawa, Kazuo Sakamoto, Hirozumi Sakai, Rinzo Soejima, Hiroshi Kawane, Yoshihiti Noki, Yoshihisa Nakagawa, Osamu Moriya, Osamu Kurimura, Hideo Sasaki, Hirofumi Fukuhara, Tadao Morimoto, Eiro Tsubura, Masakazu Tamura, Toshihiro Gotoh, Masaru Nakagawa, Koichi Fukuyama, Tadaaki Morimoto, I. Teiho, Masami Ito, Naoyoshi Kojiro, Yoshiro Sawae, Kaoru Okada, Yukio Kumagai, Hitoshi Nagano, Torao Inoue, Chiharu Kubo, Kohei Hara, Atsushi Saito, Keizo Yamaguchi, Yoji Suzuyama, Yoshiteru Shigeno, Shigeru Kohno, Koichi Watanabe, Kin Ich Izumikawa, Tsunetoshi Koteda, Kazuhiro Okuno, Takashige Miyazaki, Tsuneo Tsutsumi, Keizo Matsumoto, Harumi Shishido, Tomoyuki Harada, Masaru Nasu, Jun Goto, Yoichiro Goto, Takayoshi Tashiro, Takashi Tioga, Shykuro Araki, Masayuki Ando, Moritaka Suga, Kazumine Kobari, Masao Nakatomi, Yutoku Kinjo, Tatsuo Ohgimi, Katsuyoshi Shimoji, Yuei Irabu

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

The clinical effectiveness, safety and utility of ciprofloxacin (CPFX) in the treatment of chronic respiratory tract infections were compared with those of cefaclor (CCL) by a double dummy fashion. The following diseases were studied in this trial;i. e. infectious exacerbation of chronic bronchitis, diffuse parIbronchiolitis and other respiratory diseases, such as bronchiectasis, bronchial asthma, pulmonary emphysema, pulmonary fibrosis. Patients were orally administered with either 200 mg of CPFX or 250 mg of CCL three times a day for 14 days in principle. Out of all 230 patients, CPFX was given to 111 patients and CCL to 119 patients. Clinical effectiveness, safety and utility were evaluated on the basis of committee judgement and the results obtained were as follows. 1) The clinical effectiveness rate was 84.5% (87/103) in CPFX group and 61.9% (60/97) in CCL group, respectively. Statistically significant difference was observed between the two groups (P< 0.001). 2) Bacteriologically, the eradication rate of 75.0% (45/60) was observed in CPFX group, and that in CCL group was 52.6% (30/57) (P<0.05). The eradication rate of H. influenzae was 90.0% in CPFX group, which was significantly higher than that of the CCL group (P<0.05). 3) Side effects were noted in 5.6% among 107 patients of CPFX group and 6. 1% among 114 patients of CCL group. Abnormal changes in laboratory findings after administration were noted in 11.5% of CPFX cases group and in 11.4% of CCL cases. There was no significant difference between the rates of two groups. 4) The utility rate in CPFX group was 83.5% (86/103), which was higher than that in CCL group (P<0.001). From the above results, CPFX is assessed to be more useful in clinical use than CCL specifically in the treatment of chronic bronchitis, diffuse panbronchiolitis and other chronic complicated or intractable respiratory tract infectious diseases.

Original language	English
Pages (from-to)	1011-1037
Number of pages	27
Journal	Chemotherapy
Volume	34
Issue number	10
DOIs	https://doi.org/10.11250/chemotherapy1953.34.1011
Publication status	Published - 1986
Externally published	Yes

All Science Journal Classification (ASJC) codes

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.34.1011

Cite this

Kobayashik, H., Takamura, E., Takeda, H., Kono, K., Saito, A., Tomizawa, M., Nakayama, I., Hiraga, Y., Kikuchi, K., Yamamoto, A., Takebe, K., Kumasakak, Y., Aoyagi, A., Tamura, T., Sekino, K., Endo, K., Irie, T., Sagara, M., Okamoto, K., ... Irabu, Y. (1986). Comparative clinical study of ciprofloxacin and cefaclor in the treatment of respiratory tract infections. Chemotherapy, 34(10), 1011-1037. https://doi.org/10.11250/chemotherapy1953.34.1011

Kobayashik, H, Takamura, E, Takeda, H, Kono, K, Saito, A, Tomizawa, M, Nakayama, I, Hiraga, Y, Kikuchi, K, Yamamoto, A, Takebe, K, Kumasakak, Y, Aoyagi, A, Tamura, T, Sekino, K, Endo, K, Irie, T, Sagara, M, Okamoto, K, Tamura, M, Konishi, K, Daibo, A, Kuramitsu, H, Gomi, K, Itakura, K, Sato, N, Tanifuji, K, Takishima, T, Ida, S, Ohno, I, Konno, K, Oizumi, K, Aonuma, S, Hayashi, I, Katsu, M, Okui, S, Fukui, T, Yokose, T, Toyota, T, Kawai, M, Yamagata, H, Yoshizawa, S, Katayama, T, Aoyagi, T, Higashi, F, Masuda, G, Negishi, M, Young, C, Sato, M, Tominaga, T, Sekine, O, Usuda, Y, Aoki, N, Yamasaku, F, Suzuki, Y, Saito, A, Miyahara, T, Koyama, M, Watanabe, K, Iijima, F, Mashimo, K, Yamane, Y, Katoh, M, Tanimoto, H, Nakata, K, Nakamori, Y, Chonabayashi, N, Nakatani, R, Yoshimura, K, Ikemoto, H, Watanabe, K, Kabe, J, Ishibashi, H, Sano, Y, Kudo, K, Uno, Y, Fujimori, I, Kobayashi, Y, Obana, M, Okubo, T, Ito, A, Kurihara, M, Yamabe, K, Fukaya, K, Matsumoto, F, Odagiri, S, Matsumura, M, Suzuki, K, Murohashi, K, Suzuki, H, Yoshiike, Y, Kiuchi, M, Fukuda, T, Kusama, S, Matsuzawa, Y, Ohyama, K, Takeuchi, T, Kato, M, Hanaki, H, Yamamoto, T, Nishiyama, H, Iwata, T, Oida, K, Mochizuki, Y, Hase, M, Suzuki, Y, Ikeda, N, Fujino, S, Matsumoto, T, Tsujino, H, Bando, K, Kuroda, N, Kuze, F, Kamoto, Y, Yonezu, S, Iida, Y, Sakakibara, Y, Yasunaga, K, Ueda, Y, Ôkubo, H, Miki, F, Ikuno, Y, Inoue, E, Murata, A, Tanizawa, SI, Sakamoto, K, Sakai, H, Soejima, R, Kawane, H, Noki, Y, Nakagawa, Y, Moriya, O, Kurimura, O, Sasaki, H, Fukuhara, H, Morimoto, T, Tsubura, E, Tamura, M, Gotoh, T, Nakagawa, M, Fukuyama, K, Morimoto, T, Teiho, I, Ito, M, Kojiro, N, Sawae, Y, Okada, K, Kumagai, Y, Nagano, H, Inoue, T, Kubo, C, Hara, K, Saito, A, Yamaguchi, K, Suzuyama, Y, Shigeno, Y, Kohno, S, Watanabe, K, Izumikawa, KI, Koteda, T, Okuno, K, Miyazaki, T, Tsutsumi, T, Matsumoto, K, Shishido, H, Harada, T, Nasu, M, Goto, J, Goto, Y, Tashiro, T, Tioga, T, Araki, S, Ando, M, Suga, M, Kobari, K, Nakatomi, M, Kinjo, Y, Ohgimi, T, Shimoji, K & Irabu, Y 1986, 'Comparative clinical study of ciprofloxacin and cefaclor in the treatment of respiratory tract infections', Chemotherapy, vol. 34, no. 10, pp. 1011-1037. https://doi.org/10.11250/chemotherapy1953.34.1011

@article{12345c205c574f6d827b803a5c31459f,

title = "Comparative clinical study of ciprofloxacin and cefaclor in the treatment of respiratory tract infections",

abstract = "The clinical effectiveness, safety and utility of ciprofloxacin (CPFX) in the treatment of chronic respiratory tract infections were compared with those of cefaclor (CCL) by a double dummy fashion. The following diseases were studied in this trial;i. e. infectious exacerbation of chronic bronchitis, diffuse parIbronchiolitis and other respiratory diseases, such as bronchiectasis, bronchial asthma, pulmonary emphysema, pulmonary fibrosis. Patients were orally administered with either 200 mg of CPFX or 250 mg of CCL three times a day for 14 days in principle. Out of all 230 patients, CPFX was given to 111 patients and CCL to 119 patients. Clinical effectiveness, safety and utility were evaluated on the basis of committee judgement and the results obtained were as follows. 1) The clinical effectiveness rate was 84.5% (87/103) in CPFX group and 61.9% (60/97) in CCL group, respectively. Statistically significant difference was observed between the two groups (P< 0.001). 2) Bacteriologically, the eradication rate of 75.0% (45/60) was observed in CPFX group, and that in CCL group was 52.6% (30/57) (P<0.05). The eradication rate of H. influenzae was 90.0% in CPFX group, which was significantly higher than that of the CCL group (P<0.05). 3) Side effects were noted in 5.6% among 107 patients of CPFX group and 6. 1% among 114 patients of CCL group. Abnormal changes in laboratory findings after administration were noted in 11.5% of CPFX cases group and in 11.4% of CCL cases. There was no significant difference between the rates of two groups. 4) The utility rate in CPFX group was 83.5% (86/103), which was higher than that in CCL group (P<0.001). From the above results, CPFX is assessed to be more useful in clinical use than CCL specifically in the treatment of chronic bronchitis, diffuse panbronchiolitis and other chronic complicated or intractable respiratory tract infectious diseases.",

author = "Hiroyuki Kobayashik and Enji Takamura and Hiroaki Takeda and Kota Kono and Akira Saito and Masumi Tomizawa and Ichiro Nakayama and Yohmei Hiraga and Kohki Kikuchi and Asako Yamamoto and Kazuo Takebe and Yoshihiro Kumasakak and Azumi Aoyagi and Toyokazu Tamura and Keiichi Sekino and Katsumi Endo and Tatsuro Irie and Morio Sagara and Katsuhiro Okamoto and Masao Tamura and Kazuki Konishi and Ataru Daibo and Hiroshi Kuramitsu and Kazutoshi Gomi and Kotaro Itakura and Nobuhisa Sato and Kazuo Tanifuji and Tamotsu Takishima and Shiroh Ida and Isao Ohno and Kiyoshi Konno and Kotaro Oizumi and Seiichi Aonuma and Izumi Hayashi and Masataka Katsu and Shinji Okui and Toshio Fukui and Takashi Yokose and Takeo Toyota and Mieko Kawai and Hajime Yamagata and Shigeo Yoshizawa and Tetsuji Katayama and Teruo Aoyagi and Fuyuhiko Higashi and Gohta Masuda and Masayoshi Negishi and Chenden Young and Minoru Sato and Takehiko Tominaga and Osamu Sekine and Yoshimar Usuda and Nobuki Aoki and Fusanosuke Yamasaku and Yasutoshi Suzuki and Atsushi Saito and Tadashi Miyahara and Masaru Koyama and Kentaro Watanabe and Fukuo Iijima and Keimei Mashimo and Yoshiji Yamane and Masakazu Katoh and Hiroichi Tanimoto and Koichiro Nakata and Yoshitaka Nakamori and Naohiko Chonabayashi and Ryuo Nakatani and Kunihiko Yoshimura and Hideo Ikemoto and Kazuyoshi Watanabe and Junzaburo Kabe and Hiroyoshi Ishibashi and Yasuyuki Sano and Koichiro Kudo and Yuko Uno and Ippei Fujimori and Yoshio Kobayashi and Mitsuo Obana and Takao Okubo and Akira Ito and Makio Kurihara and Kaitaro Yamabe and Kazufuto Fukaya and Fumio Matsumoto and Shigeki Odagiri and Masanori Matsumura and Kaneo Suzuki and Koou Murohashi and Hisako Suzuki and Yasuhiro Yoshiike and Mitsuyo Kiuchi and Tsutomu Fukuda and Shozo Kusama and Yukinori Matsuzawa and Kaoru Ohyama and Toshihiko Takeuchi and Masahito Kato and Hidekazu Hanaki and Toshiyuki Yamamoto and Hideki Nishiyama and Takekuni Iwata and Kazukiyo Oida and Yoshiro Mochizuki and Mitsuo Hase and Yujiro Suzuki and Nobuaki Ikeda and Shozo Fujino and Tetsuya Matsumoto and Hiroyuki Tsujino and Kenji Bando and Naoaki Kuroda and Fumiyuki Kuze and Yuruko Kamoto and Seibun Yonezu and Yube Iida and Yoshihiko Sakakibara and Kōjiro Yasunaga and Yoshihiro Ueda and Hiroshi {\^O}kubo and Fumio Miki and Yoshiyasu Ikuno and Eiji Inoue and Akihito Murata and Tanizawa, {Shin Ich} and Kazuo Sakamoto and Hirozumi Sakai and Rinzo Soejima and Hiroshi Kawane and Yoshihiti Noki and Yoshihisa Nakagawa and Osamu Moriya and Osamu Kurimura and Hideo Sasaki and Hirofumi Fukuhara and Tadao Morimoto and Eiro Tsubura and Masakazu Tamura and Toshihiro Gotoh and Masaru Nakagawa and Koichi Fukuyama and Tadaaki Morimoto and I. Teiho and Masami Ito and Naoyoshi Kojiro and Yoshiro Sawae and Kaoru Okada and Yukio Kumagai and Hitoshi Nagano and Torao Inoue and Chiharu Kubo and Kohei Hara and Atsushi Saito and Keizo Yamaguchi and Yoji Suzuyama and Yoshiteru Shigeno and Shigeru Kohno and Koichi Watanabe and Izumikawa, {Kin Ich} and Tsunetoshi Koteda and Kazuhiro Okuno and Takashige Miyazaki and Tsuneo Tsutsumi and Keizo Matsumoto and Harumi Shishido and Tomoyuki Harada and Masaru Nasu and Jun Goto and Yoichiro Goto and Takayoshi Tashiro and Takashi Tioga and Shykuro Araki and Masayuki Ando and Moritaka Suga and Kazumine Kobari and Masao Nakatomi and Yutoku Kinjo and Tatsuo Ohgimi and Katsuyoshi Shimoji and Yuei Irabu",

year = "1986",

doi = "10.11250/chemotherapy1953.34.1011",

language = "English",

volume = "34",

pages = "1011--1037",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

number = "10",

}

TY - JOUR

T1 - Comparative clinical study of ciprofloxacin and cefaclor in the treatment of respiratory tract infections

AU - Kobayashik, Hiroyuki

AU - Takamura, Enji

AU - Takeda, Hiroaki

AU - Kono, Kota

AU - Saito, Akira

AU - Tomizawa, Masumi

AU - Nakayama, Ichiro

AU - Hiraga, Yohmei

AU - Kikuchi, Kohki

AU - Yamamoto, Asako

AU - Takebe, Kazuo

AU - Kumasakak, Yoshihiro

AU - Aoyagi, Azumi

AU - Tamura, Toyokazu

AU - Sekino, Keiichi

AU - Endo, Katsumi

AU - Irie, Tatsuro

AU - Sagara, Morio

AU - Okamoto, Katsuhiro

AU - Tamura, Masao

AU - Konishi, Kazuki

AU - Daibo, Ataru

AU - Kuramitsu, Hiroshi

AU - Gomi, Kazutoshi

AU - Itakura, Kotaro

AU - Sato, Nobuhisa

AU - Tanifuji, Kazuo

AU - Takishima, Tamotsu

AU - Ida, Shiroh

AU - Ohno, Isao

AU - Konno, Kiyoshi

AU - Oizumi, Kotaro

AU - Aonuma, Seiichi

AU - Hayashi, Izumi

AU - Katsu, Masataka

AU - Okui, Shinji

AU - Fukui, Toshio

AU - Yokose, Takashi

AU - Toyota, Takeo

AU - Kawai, Mieko

AU - Yamagata, Hajime

AU - Yoshizawa, Shigeo

AU - Katayama, Tetsuji

AU - Aoyagi, Teruo

AU - Higashi, Fuyuhiko

AU - Masuda, Gohta

AU - Negishi, Masayoshi

AU - Young, Chenden

AU - Sato, Minoru

AU - Tominaga, Takehiko

AU - Sekine, Osamu

AU - Usuda, Yoshimar

AU - Aoki, Nobuki

AU - Yamasaku, Fusanosuke

AU - Suzuki, Yasutoshi

AU - Saito, Atsushi

AU - Miyahara, Tadashi

AU - Koyama, Masaru

AU - Watanabe, Kentaro

AU - Iijima, Fukuo

AU - Mashimo, Keimei

AU - Yamane, Yoshiji

AU - Katoh, Masakazu

AU - Tanimoto, Hiroichi

AU - Nakata, Koichiro

AU - Nakamori, Yoshitaka

AU - Chonabayashi, Naohiko

AU - Nakatani, Ryuo

AU - Yoshimura, Kunihiko

AU - Ikemoto, Hideo

AU - Watanabe, Kazuyoshi

AU - Kabe, Junzaburo

AU - Ishibashi, Hiroyoshi

AU - Sano, Yasuyuki

AU - Kudo, Koichiro

AU - Uno, Yuko

AU - Fujimori, Ippei

AU - Kobayashi, Yoshio

AU - Obana, Mitsuo

AU - Okubo, Takao

AU - Ito, Akira

AU - Kurihara, Makio

AU - Yamabe, Kaitaro

AU - Fukaya, Kazufuto

AU - Matsumoto, Fumio

AU - Odagiri, Shigeki

AU - Matsumura, Masanori

AU - Suzuki, Kaneo

AU - Murohashi, Koou

AU - Suzuki, Hisako

AU - Yoshiike, Yasuhiro

AU - Kiuchi, Mitsuyo

AU - Fukuda, Tsutomu

AU - Kusama, Shozo

AU - Matsuzawa, Yukinori

AU - Ohyama, Kaoru

AU - Takeuchi, Toshihiko

AU - Kato, Masahito

AU - Hanaki, Hidekazu

AU - Yamamoto, Toshiyuki

AU - Nishiyama, Hideki

AU - Iwata, Takekuni

AU - Oida, Kazukiyo

AU - Mochizuki, Yoshiro

AU - Hase, Mitsuo

AU - Suzuki, Yujiro

AU - Ikeda, Nobuaki

AU - Fujino, Shozo

AU - Matsumoto, Tetsuya

AU - Tsujino, Hiroyuki

AU - Bando, Kenji

AU - Kuroda, Naoaki

AU - Kuze, Fumiyuki

AU - Kamoto, Yuruko

AU - Yonezu, Seibun

AU - Iida, Yube

AU - Sakakibara, Yoshihiko

AU - Yasunaga, Kōjiro

AU - Ueda, Yoshihiro

AU - Ôkubo, Hiroshi

AU - Miki, Fumio

AU - Ikuno, Yoshiyasu

AU - Inoue, Eiji

AU - Murata, Akihito

AU - Tanizawa, Shin Ich

AU - Sakamoto, Kazuo

AU - Sakai, Hirozumi

AU - Soejima, Rinzo

AU - Kawane, Hiroshi

AU - Noki, Yoshihiti

AU - Nakagawa, Yoshihisa

AU - Moriya, Osamu

AU - Kurimura, Osamu

AU - Sasaki, Hideo

AU - Fukuhara, Hirofumi

AU - Morimoto, Tadao

AU - Tsubura, Eiro

AU - Tamura, Masakazu

AU - Gotoh, Toshihiro

AU - Nakagawa, Masaru

AU - Fukuyama, Koichi

AU - Morimoto, Tadaaki

AU - Teiho, I.

AU - Ito, Masami

AU - Kojiro, Naoyoshi

AU - Sawae, Yoshiro

AU - Okada, Kaoru

AU - Kumagai, Yukio

AU - Nagano, Hitoshi

AU - Inoue, Torao

AU - Kubo, Chiharu

AU - Hara, Kohei

AU - Saito, Atsushi

AU - Yamaguchi, Keizo

AU - Suzuyama, Yoji

AU - Shigeno, Yoshiteru

AU - Kohno, Shigeru

AU - Watanabe, Koichi

AU - Izumikawa, Kin Ich

AU - Koteda, Tsunetoshi

AU - Okuno, Kazuhiro

AU - Miyazaki, Takashige

AU - Tsutsumi, Tsuneo

AU - Matsumoto, Keizo

AU - Shishido, Harumi

AU - Harada, Tomoyuki

AU - Nasu, Masaru

AU - Goto, Jun

AU - Goto, Yoichiro

AU - Tashiro, Takayoshi

AU - Tioga, Takashi

AU - Araki, Shykuro

AU - Ando, Masayuki

AU - Suga, Moritaka

AU - Kobari, Kazumine

AU - Nakatomi, Masao

AU - Kinjo, Yutoku

AU - Ohgimi, Tatsuo

AU - Shimoji, Katsuyoshi

AU - Irabu, Yuei

PY - 1986

Y1 - 1986

N2 - The clinical effectiveness, safety and utility of ciprofloxacin (CPFX) in the treatment of chronic respiratory tract infections were compared with those of cefaclor (CCL) by a double dummy fashion. The following diseases were studied in this trial;i. e. infectious exacerbation of chronic bronchitis, diffuse parIbronchiolitis and other respiratory diseases, such as bronchiectasis, bronchial asthma, pulmonary emphysema, pulmonary fibrosis. Patients were orally administered with either 200 mg of CPFX or 250 mg of CCL three times a day for 14 days in principle. Out of all 230 patients, CPFX was given to 111 patients and CCL to 119 patients. Clinical effectiveness, safety and utility were evaluated on the basis of committee judgement and the results obtained were as follows. 1) The clinical effectiveness rate was 84.5% (87/103) in CPFX group and 61.9% (60/97) in CCL group, respectively. Statistically significant difference was observed between the two groups (P< 0.001). 2) Bacteriologically, the eradication rate of 75.0% (45/60) was observed in CPFX group, and that in CCL group was 52.6% (30/57) (P<0.05). The eradication rate of H. influenzae was 90.0% in CPFX group, which was significantly higher than that of the CCL group (P<0.05). 3) Side effects were noted in 5.6% among 107 patients of CPFX group and 6. 1% among 114 patients of CCL group. Abnormal changes in laboratory findings after administration were noted in 11.5% of CPFX cases group and in 11.4% of CCL cases. There was no significant difference between the rates of two groups. 4) The utility rate in CPFX group was 83.5% (86/103), which was higher than that in CCL group (P<0.001). From the above results, CPFX is assessed to be more useful in clinical use than CCL specifically in the treatment of chronic bronchitis, diffuse panbronchiolitis and other chronic complicated or intractable respiratory tract infectious diseases.

AB - The clinical effectiveness, safety and utility of ciprofloxacin (CPFX) in the treatment of chronic respiratory tract infections were compared with those of cefaclor (CCL) by a double dummy fashion. The following diseases were studied in this trial;i. e. infectious exacerbation of chronic bronchitis, diffuse parIbronchiolitis and other respiratory diseases, such as bronchiectasis, bronchial asthma, pulmonary emphysema, pulmonary fibrosis. Patients were orally administered with either 200 mg of CPFX or 250 mg of CCL three times a day for 14 days in principle. Out of all 230 patients, CPFX was given to 111 patients and CCL to 119 patients. Clinical effectiveness, safety and utility were evaluated on the basis of committee judgement and the results obtained were as follows. 1) The clinical effectiveness rate was 84.5% (87/103) in CPFX group and 61.9% (60/97) in CCL group, respectively. Statistically significant difference was observed between the two groups (P< 0.001). 2) Bacteriologically, the eradication rate of 75.0% (45/60) was observed in CPFX group, and that in CCL group was 52.6% (30/57) (P<0.05). The eradication rate of H. influenzae was 90.0% in CPFX group, which was significantly higher than that of the CCL group (P<0.05). 3) Side effects were noted in 5.6% among 107 patients of CPFX group and 6. 1% among 114 patients of CCL group. Abnormal changes in laboratory findings after administration were noted in 11.5% of CPFX cases group and in 11.4% of CCL cases. There was no significant difference between the rates of two groups. 4) The utility rate in CPFX group was 83.5% (86/103), which was higher than that in CCL group (P<0.001). From the above results, CPFX is assessed to be more useful in clinical use than CCL specifically in the treatment of chronic bronchitis, diffuse panbronchiolitis and other chronic complicated or intractable respiratory tract infectious diseases.

UR - http://www.scopus.com/inward/record.url?scp=0022977543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022977543&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.34.1011

DO - 10.11250/chemotherapy1953.34.1011

M3 - Article

AN - SCOPUS:0022977543

SN - 0009-3165

VL - 34

SP - 1011

EP - 1037

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

IS - 10

ER -

Comparative clinical study of ciprofloxacin and cefaclor in the treatment of respiratory tract infections

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this